[1] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. [2] Siegel RL, Miller KD, Fuchs HE, et al.Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. [3] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. [4] Cramer JD, Burtness B, Le QT, et al.The changing therapeutic landscape of head and neck cancer[J]. Nat Rev Clin Oncol, 2019, 16(11): 669-683. [5] Tinhofer I, Braunholz D, Klinghammer K.Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies[J]. Cancers Head Neck, 2020, 5: 9. [6] Antoni D, Burckel J, Josset E, et al.Three-dimensional cell culture: a breakthrough in vivo[J]. Int J Mol Sci, 2015, 16(3): 5517-5527. [7] Souza FH, Silva RM, Campos-Fernandez C, et al.Comparative assay of 2D and 3D cell culture models: proliferation, gene expression and anticancer drug response[J]. Curr Pharm Des, 2018, 24(15): 1689-1694. [8] Driehuis E, Kolders S, Spelier M, et al.Oral mucosal organoids as a potential platform for personalized cancer therapy[J]. Cancer Discov, 2019, 9(7): 852-871. [9] Driehuis E, Kretzschmar K, Clevers H, et al.Establishment of patient-derived cancer organoids for drug-screening applications[J]. Nat Protoc, 2020, 15(10): 3380-3409. [10] Motz GT, Santoro SA, Wang L, et al.Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors[J]. Nat Med, 2014, 20(6): 607-615. [11] Kim J, Lee J, Kim H, et al.ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming[J]. Stem Cell Res Ther, 2023, 14(1): 41. [12] Sinha T, Lammerts van Bueren K, Dickel DE, et al. Differential Etv2 threshold requirement for endothelial and erythropoietic development[J]. Cell Rep, 2022, 39(9): 110881. [13] Steimle JD, Kim J, Rowton MJ, et al.ETV2 primes hematoendothelial gene enhancers prior to hematoendothelial fate commitment[J]. Cell Rep, 2023, 42(6): 112665. [14] Zhao Y, Xu J, Xiao Y, et al.Review on the vascularization of organoids and organoids-on-a-chip[J]. Front Bioeng Biotechnol, 2021, 9: 637048. [15] Strobel C, Moss T, Hoying JB, et al.Vascularized tissue organoids[J]. Bioengineering (Basel), 2023, 10(2): 124. [16] Nashimoto T, Hayashi Y, Kunita A, et al.Integrating perfusable vascular networks with a three-dimensional tissue in a microfluidic device[J]. Integr Biol (Camb), 2017, 9(6):506-518. [17] Paek J, Park J, Lu M, et al.Microphysiological engineering of self-assembled and perfusable microvascular beds for the production of vascularized three-dimensional human microtissues[J]. ACS Nano, 2019, 13(7): 7627-7643. [18] Lancaster MA.Brain organoids get vascularized[J]. Nat Biotechnol, 2018, 36(5): 407-408. [19] Sachs N, de Ligt J, Kopper O, et al. A living biobank of breast cancer organoids captures disease heterogeneity[J]. Cell, 2018, 172(1-2): 373-386.e10. [20] Palikuqi B, Nguyen M, Li J, et al.Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis[J]. Nature, 2020, 585(7825): 426-432. [21] 许博闻, 何佳, 高文博, 等. 血管内皮细胞条件培养基对肝癌细胞上皮-间质转化的影响[J]. 生物医学工程学杂志, 2020, 37(3): 442-449. Xu BW, He J, Gao WB, et al.Effect of conditioned medium of vascular endothelial cells on the epithelial-mesenchymal transition of hepatocellular carcinoma cells[J]. Journal of Biomedical Engineering, 2020, 37(3): 442-449. [22] Qin X, Cardoso Rodriguez F, Sufi J, et al. An oncogenic phenoscape of colonic stem cell polarization[J]. Cell, 2023, 186(25): 5554-5568.e18. |